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Background: Major abdominal surgery is associated with significant risk of morbidity and mortality in the
perioperative period. Optimising intraoperative fluid administration may result in improved outcomes. Our aim
was to compare the effects of central venous pressure (CVP), and central venous oxygen saturation (ScvO2)-assisted
fluid therapy on postoperative complications in patients undergoing high risk surgery.
Methods: Patients undergoing elective major abdominal surgery were randomised into control and ScvO2 groups. The
target level of mean arterial pressure (MAP) was≥ 60 mmHg in both groups. In cases of MAP < 60 mmHg patients
received either a fluid or vasopressor bolus according to the CVP < 8 mmHg in the control group. In the ScvO2 group,
in addition to the MAP, an ScvO2 of <75 % or a >3 % decrease indicated need for intervention, regardless of the actual
MAP. Data are presented as mean ± standard deviation or median (interquartile range).
Results: We observed a lower number of patients with complications in the ScvO2 group compared to the control
group, however it did not reach statistical significance (ScvO2 group: 10 vs. control group: 19; p = 0.07). Patients in the
ScvO2 group (n = 38) received more colloids compared to the control group (n = 41) [279(161) vs. 107(250) ml/h;
p < 0.001]. Both groups received similar amounts of crystalloid (1126 ± 471 vs. 1049 ± 431 ml/h; p = 0.46) and
norepinephrine [37(107) vs. 18(73) mcg/h; p = 0.84]. Despite similar blood loss in both groups, the ScvO2 group
received more blood transfusions (63 % vs. 37 %; p = 0.018). More patients in the control group had a postoperative
PaO2/FiO2 < 200 mmHg (23 vs. 10, p < 0.01). Twenty eight day survival was significantly higher in the ScvO2 group
(37/38 vs. 33/41 p = 0.018).
Conclusion: ScvO2-assisted intraoperative haemodynamic support provided some benefits, including significantly
better postoperative oxygenation and 28 day survival rate, compared to CVP-assisted therapy without a significant
effect on postoperative complications during major abdominal surgery.
Trial registration: ClinicalTrials.gov NCT02337010.
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There are an estimated 234 million surgical operations
worldwide every year, with significant risk of morbidity
and mortality in the perioperative period in patients
undergoing major surgery [1]. Following the implemen-
tation of safety standards outcomes after anaesthesia
have improved, although estimations of perioperative
complications and postoperative morbidity are difficult.
It has been suggested this may be between 3 and 17 % of
cases [2, 3].
Several studies have revealed that inappropriate intra-
operative fluid therapy may be responsible for postop-
erative complications and organ failure. Excessive fluid
administration during surgical procedures may lead to
more frequent postoperative complications [4, 5], while
restrictive fluid therapy may improve outcome after
major elective gastrointestinal surgery [6]. On the other
hand, fluid restriction may increase the level of hypo-
volemia and hence hypoperfusion, and thereby in-
creased incidence of postoperative complications [7].
It is well known, that using heart rate (HR), mean
arterial pressure (MAP) and central venous pressure
(CVP) to assess and guide haemodynamic support may
be misleading [8–10].
Advanced haemodynamic monitoring, using cardiac
output, stroke volume, stroke volume variation (SVV),
pulse pressure variation (PPV) to guide intraoperative
fluid therapy has resulted in improved outcomes in
several studies [11–14]. Despite the increasing evidence,
advanced haemodynamic monitoring has not become
routine practice and, in high risk patients, arterial and
central venous pressure monitoring remain the most
common tools applied in more than 80 % of cases in
Europe and in the United States [15]. One of the reasons
may be that accurate measurement of cardiac output,
SVV and PPV require advanced instrumentation.
Another important factor for haemodynamic stability
is the balance between oxygen delivery (DO2) and con-
sumption (VO2). Unfortunately, detailed haemodynamic
evaluation, including DO2/VO2 balance, for every high
risk patient in the operating theatre is not feasible. The
most often used bedside parameter to assess the rela-
tionship between oxygen supply and consumption is the
central venous oxygen saturation (ScvO2). Continuous
monitoring of the ScvO2 is also possible with a device
based on fiber-optic technology via a standard central
venous catheter. Values measured by this approach have
shown good correlation with laboratory values [16].
ScvO2 reflects important changes in the DO2/VO2 rela-
tionship, has been found to be useful during high-risk
surgery, and low ScvO2 is associated with increased
postoperative complications [17, 18]. Despite these
theoretical advantages, ScvO2 is only used in 12–30 %
of high risk surgical patients [15]. In clinical routine,MAP and CVP are the most frequently applied moni-
toring tools (75–95 %) during high risk surgery [15],
despite convincing evidence that neither can predict
fluid responsiveness [8–10].
Therefore, the aim of the current study was to com-
pare the effects of ScvO2 assisted intraoperative
haemodynamic support to the routinely used MAP-
CVP approach on postoperative complications in high
risk surgical patients.
Methods
Patients
Following Regional Ethics Committee approval (details
are summarised below) and obtaining written informed
consent, all patients undergoing the following elective
major abdominal surgeries, including oesophagectomy,
total gastrectomy, radical cystectomy, aorto-bifemoral
bypass or elective repair of abdominal aortic aneurysm,
were enrolled into our prospective study. After surgery
all patients were admitted to our intensive care unit
(ICU) in Department of Anaesthesiology and Intensive
Therapy, University of Szeged, Hungary. Exclusion
criteria were pre-existing chronic organ insufficiency as
determined by the Acute Physiology and Chronic Health
Evaluation (APACHE) II scoring system, New York
Heart Association Class IV, chronic hypoxia or hyper-
capnia, chronic renal failure requiring renal replacement
therapy, biopsy proven cirrhosis or portal hypertension
and immunodeficiency [19]. Furthermore, in cases of
preoperative anaemia (haemoglobin < 100 g/L), coagula-
tion abnormality, and patients with chronic use of corti-
costeriods and non-steroid anti-inflammatory drugs
were also excluded. Patients requiring an operation due
to malignant disease where the tumour then proved to
be inoperable were also excluded.
Patients were randomly allocated by envelope ran-
domisation in a block-of-ten fashion into control, or
ScvO2 groups.
Anaesthesia and monitoring
All patients received routine anaesthetic management,
premedication with oral benzodiazepine, induction with
propofol (1–2 mg/kg), muscle relaxation with rocuro-
nium (0.6 mg/kg) and analgesia with intravenous fen-
tanyl (0.7–1 mcg/kg/dose). If an epidural catheter was
inserted, it was tested with 60 mg lignocaine but during
the operation only intravenous analgesia was used to
prevent hypotension caused by epidural analgesia.
Anaesthesia was maintained with sevoflurane (minimum
alveolar concentration (MAC): 1.0–1.2). After endo-
tracheal intubation, arterial and internal jugular central
venous catheters were inserted. During the surgical pro-
cedures haemodynamic parameters (heart rate, invasive
blood pressure, CVP), oxygen saturation (SaO2), end-
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were monitored. Ventilation was maintained with a
peep end-expiratory pressure of 4 cmH2O, tidal vol-
ume 6–8 ml/kg and fraction of inspired oxygen (FiO2)
0.4–0.5 to maintain SaO2 > 94 % and end-tidal CO2
tension of 35–40 mmHg. In all patients lactated
Ringer’s solution (10–15 ml/kg/h) was infused as the
baseline volume replacement. Arterial and central
venous blood samples were taken hourly for blood gas
analysis. The amount of crystalloid and colloid infu-
sion administered, the demand and dose of vasopres-
sor/inotropic support and blood transfusions were all
recorded at the end of surgery.
Measurement of ScvO2
Central venous saturation was continuously monitored
in the ScvO2 group by using a CeVOX monitor (Pulsion
Medical Systems, Munich, Germany). The CeVOX probe
(PV2022-37; Pulsion Medical Systems, Munich, Germany)
was inserted into the internal jugular central venous
catheter as described in the manufacturer’s users manual.
The position of the central venous catheter in the superior
vena cava was confirmed by chest X-ray postoperatively.
The system was calibrated in vivo for ScvO2 measure-
ments by laboratory co-oximeter (Cobas b 221, Roche
Ltd, Basel, Switzerland). Calibration, if necessary, was
repeated at least hourly during the surgical procedure. In
the control group the level of central venous saturation
was measured hourly by laboratory co-oximeter.
Interventions and protocol
The anaesthetist responsible for the patient was blinded
to the ScvO2 in the control group and to the CVP in
the ScvO2 group. Regarding interventions in general, if
hypovolaemia was suspected (see below) fluid bolus
was given in the form of 250 ml hydroxyethyl starch
solution (HES, 6 % hydroxyethyl starch 130/0.4 in 0.9 %
sodium chloride, Voluven, Fresenius Kabi, Germany) overMAP<60 mmHg 
Yes No 
HES 250 ml NE 10 mcg 
CVP < 8 mmHg 
ScvO2<75% 
HES 25
Control group 
Fig. 1 Flowchart of the study design. MAP: mean arterial pressure, CVP: cen
hydroxyethyl starch, NE: norepinephrine15 min. If hypovolaemia was unlikely, but hypotension
was present this was treated with a vasopressor (10 mcg
bolus or continuous infusion of norepinephrine).
In the control group cases of hypotension (as de-
fined by MAP < 60 mmHg) were treated with a fluid
bolus if the CVP < 8 mmHg, and norepinephrine if the
CVP ≥ 8 mmHg, reflecting the clinical routine. These
target values are also recommended in several (albeit
not intra-operative), guidelines [20, 21].
In the ScvO2 group, hypotension (MAP < 60 mmHg)
was considered primarily due to hypovolaemia if the
ScvO2 < 75 %, and patients received a fluid bolus. If the
ScvO2 ≥ 75 %, it was assumed that hypotension was pri-
marily due to vasodilatation caused by general anaesthe-
sia, and norepinephrine was administrated. In addition
to low MAP there was also another trigger for interven-
tion in this group: if ScvO2 dropped below 75 % or there
was a sudden decrease by more than >3 %, patients re-
ceived a fluid bolus regardless of the MAP. The main
steps of the protocol are summarised in Fig. 1. The
effect of the administered fluid bolus was reassessed in
every 15 min. It is important to note that in cases of per-
sistent hypotension treated by the fluid bolus as per the
study protocol, anaesthetists were allowed to administer
norepinephrine boluses in both groups and the amount
given was recorded and added to the total dose calcu-
lated at the end of surgery. Intraoperative transfusion
was indicated if the haemoglobin level was below 80 g/l
as determined by blood gas analysis. Intraoperative
blood recovery techniques were not used.
During the operation arterial and central venous blood
gas analysis were done hourly. Blood samples for labora-
tory assessments such as kidney function, liver function,
blood count and inflammatory parameters such as pro-
calcitonin (PCT) and C-reactive protein (CRP) were
taken before the operation, on arrival to the ICU and 24,
48 h later. Arterial and central venous blood gas analyses
were also performed at these time points.or    >3%
0 ml 
MAP < 60 mmHg 
ScvO2<75%
Yes No 
HES 250 ml NE 10 mcg 
ScvO2 - group 
tral venous pressure, ScvO2: central venous oxygen saturation, HES:
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All data are presented as mean ± SD or median (inter-
quartile range) as indicated by data distribution tested
by the Shapiro-Wilk test. Independent samples T-test or
Mann–Whitney U test were used to compare the data
between the two groups depending on data distribution
in each measurement. To evaluate changes in the mea-
sured parameters over time within the groups, two-way
analysis of variance (ANOVA) was used. To assess the
difference between categorical data we used Pearson’s
chi-squared test.
The main outcome parameter was the incidence of
postoperative complications on the first and second
postoperative day. We calculated the number of patients
observed with pulmonary, circulation, abdominal, renal,
infectious or surgical complications based on a previous
study by Mayer at al. [22]. Following completion of the
study, respiratory complications and acute kidney injury
were analysed post hoc. Pulmonary function was
assessed by using the ratio of arterial partial oxygen ten-
sion and the fraction of inspired oxygen (PaO2/FiO2)
according to the Berlin definition of acute respiratory
distress syndrome [23]. To assess the severity of kidney
disease we used the Kidney Disease Improving Global
Outcome (KDIGO) acute kidney injury definition [24].
Secondary end points were the difference in intraopera-
tive fluid and vasopressor requirements. Based on the re-
sults of a previous study on a similar patient population
[22], it was found that in the control group the incidence
of organ dysfunction was 50 %, whereas in the goal di-
rected therapy group it was only 20 % (i.e. the difference
was 30 %). Therefore, to have 80 % power if the p < 0.05
with Pearson’s chi-squared test, the required number of
patients should be a minimum of 40 per group. ForFig. 2 CONSORT flow diagram of the studystatistical analysis the Statistical Package for Social
Sciences (SPSS version 20, IBM Corporation, Armonk,
NY, United States) software for Windows was used.
Statistical significance was considered at p < 0.05.
Ethics
Ethical approval for this study (2618 – 2/2010.) was pro-
vided by the Regional Ethical Committee of University
of Szeged, Albert Szent-Györgyi Health Center, Szeged,
Hungary (Chairperson: Prof. Tibor Wittmann) in 2010.
Results
Eighty five patients met the inclusion criteria between
2011 and 2013. One patient was excluded due to chronic
renal failure hence 42 patients were randomized to each
group. Four patients in the ScvO2 group and 1 patient in
the control group had to be withdrawn from the study
due to the inoperability of the tumour (Fig. 2). There
were no significant differences between the two groups
regarding demographics and clinical characteristics. Five
patients in the control group were not extubated at the
end of the surgery, 4 of whom were extubated on the
first postoperative day and one patient was ventilated for
11 days. In the ScvO2 group, all patients were extubated
at the end of surgery apart from 2 patients who were
extubated on the first postoperative day and 1 patient
who was ventilated for 3 days. Following extubation all
patients received oxygen supplementation via a 28 % or
40 % Venturi face mask to maintain SaO2 > 94 %. Two
patients died in the ICU in the control group with
28 days survival also significantly lower in this group
(Table 1).
There was no significant difference in ScvO2 between
the two groups at baseline. During the operation there
Table 1 Demography of the patients. Data are shown as mean ± SD or median (interquartile)
ScvO2 (n = 38) Control (n = 41) p
Age (years) 62 ± 8 62 ± 8 0.95
Sex (M/F) 28/10 29/12 0.77
APACHE II 12 ± 4 11 ± 5 0.37
ICU LOS (days) 3 (2) 3 (2) 0.663
Length of operation (min) 247 ± 82 254 ± 45 0.76
Oesophagectomy (number of patients) 4 2
Total gastrectomy (number of patients) 3 0
Cystectomy (number of patients) 22 29
Aortobifemoral bypass (number of patients) 5 7
Aortic aneurysm (number of patients) 4 3
ICU survival (S/NS) 38/0 39/2 0.17
28 day survival (S/NS) 37/1 33/8 0.018*
*: p<0.05
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remained almost unchanged in the control group, reach-
ing a significant difference between the two groups four
hours after the start of the operation (Fig. 3). The target
MAP was achieved in most cases with no difference
between the groups (Fig. 4). Regarding the CVP there
was no significant difference between the two groups
throughout the operation (Fig. 5). Measurement of the
urine output during the operation was complicated in 33
patients who underwent radical cystectomy. However, in
cases where exact measurement was possible, hourly
urine output showed a significant difference between the
two groups: ScvO2 group (n = 23): 165 ± 98 ml/h vs. con-
trols (n = 23): 109 ± 92 ml/h, p = 0.023. Although less
patients had at least one hypotensive episode during sur-
gery in the ScvO2 group (17 vs. 25 in the control group),
this difference was not statistically significant (p = 0.18).
Patients received more colloid intraoperatively in the60
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Fig. 3 Changes in central venous saturation (ScvO2) during the operation.ScvO2 group, while the amount of crystalloid infusion
administered was similar in both groups. The number of
patients who received an intraoperative blood transfu-
sion was also significantly higher in the ScvO2 group,
although intraoperative blood loss was similar in both
groups (Table 2). The haemoglobin levels at the start
(ScvO2 group: 108 ± 19 g/l vs. control: 109 ± 22 g/l) and
the end of the operation showed no significant difference
(ScvO2 group: 94 ± 14 g/l vs. control: 97 ± 17 g/l). The
lactate levels were normal in both groups during the
whole operation without any significant difference or
change (Fig. 6). There was no difference between the
two groups in the number of patients with vasopressor
support and their vasopressor demand during the oper-
ation (Table 2).
Regarding postoperative complications, there were
more patients with complications in the control group
but it did not reach statistical significance. However,3 4 5
tion (hours)
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ScvO2
*
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Fig. 4 Changes in mean arterial pressure (MAP) during the operation. Data are shown as mean and standard deviation
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FiO2 ratio were significantly higher on the first and
second postoperative day in the control group (Table 3).
There was no difference regarding the dose of
fentanyl used during the operation (ScvO2: 179 [70]
mcg/h vs. control: 167 [77] mcg/h, p = 0.06). The MAC
of sevoflurane remained between 1.0 and 1.2 during the
whole operation for both groups with no significant
difference.
There were no significant differences in any of the inves-
tigated inflammatory markers (CRP, leucocyte count, fever,
microalbuminuria – data not shown) throughout the
perioperative period. PCT also showed almost identical kin-
etics and absolute values in the two groups at t0–24–48
(ScvO2: 0.06 [0.00] - 0.66 [1.21] - 0.45 [0.98]; controls: 0.06
[0.01] - 0.53 [1.4] - 0.42 [1.03] ng/ml, respectively).
Discussion
In this prospective randomised study we found that ScvO2
and MAP based intraoperative haemodynamic manage-
ment resulted in more intraoperative interventions, better0
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Fig. 5 Changes in central venous pressure (CVP) during the operation. Datintraoperative diuresis and less pulmonary dysfunction in
the postoperative period compared to a MAP and CVP
guided therapy, however the overall complication rate was
not reduced significantly.
ScvO2 during intraoperative haemodynamic management
It has been shown that ScvO2 is a reliable parameter to
assess the balance between oxygen supply and demand
in critically ill patients [20, 25, 26]. Although controversy
still exists about the interpretation of ScvO2, it is univer-
sally accepted that “low” values suggest a global oxygen
debt [26] and subsequently a Collaborative Study Group
has warranted clinical trials be performed with goal-
directed therapy using ScvO2 as a target in high-risk sur-
gical patients [18].
In one of the first studies on this subject it was found
that reduced ScvO2 in the postoperative period is related
to increased post-operative complications. The best cut-
off value of ScvO2 for predicting complications was
found to be 64.4 % in the early post-operative period
[17]. However, the “target” or in other words “normal”3 4 5
ion (hours)
Control
ScvO2
a are shown as mean and standard deviation
Table 2 Intraoperative interventions. Data are shown as mean ± SD or median (interquartile)
ScvO2 (n = 38) Control (n = 41) p
Crystalloid (ml/h) 1126 ± 471 1049 ± 431 0.46
Colloid (ml/h) 279 (161) 107 (250) <0.001*
Number of patients needing vasopressor 11 15 0.47
Dose of vasopressor (mcg/h) 37 (107) 18 (73) 0.84
Number of patients receiving blood transfusion 24 15 0.02*
Blood loss during the operation (ml) 973 ± 473 983 ± 574 0.99
*: p<0.05
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ScvO2 should be “higher” than the physiological value deter-
mined in awake subjects or found in patients in ICU, due to
the reduced oxygen demand/consumption during general
anaesthesia. In a recent study in which pre- and postopera-
tive ScvO2 values were investigated in patients undergoing
major abdominal surgery, the critical value was suggested to
be 73 % [18]. There is also data that keeping the oxygen ex-
traction ratio (calculated from the arterial and central ven-
ous oxygen saturation) below 27 % resulted in less
postoperative organ dysfunction and reduced hospital stay
in high-risk surgical patients [27]. In a recent observational
study in surgical patients, even higher levels of ScvO2 have
been reported (84.7 ± 8.3 %) [28]. We had similar findings in
a previous pilot study, in which the median ScvO2 was 81 %
for the whole sample [29]. Therefore, in the current study
we decided to use an interventional threshold of ScvO2 ≤
75 % or a decrease of >3 %, and observed more therapeutic
interventions compared to the MAP and CVP guided con-
trol group: patients received more fluid and blood transfu-
sions. Any decrease in DO2 might have been recognised
earlier by ScvO2 than CVP and resulted in more frequent
interventions, similar to the results of Rivers et al., who (al-
though in septic patients) also found that the patients
assigned to early goal-directed therapy received signifi-
cantly more fluid, more red-cell transfusions and0
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Fig. 6 Changes in lactate level during the operation. Data are shown as minotropic support in the initial phase of resuscitation
[20]. As there was no difference between the groups in
the haemoglobin levels at the start and at the end of
the operation, and the intraoperative blood loss was
similar in both groups, the increased use of fluid in
the ScvO2 group may had caused dilutional anaemia
and the need for more frequent transfusion in this
group. These interventions possibly resulted in better
tissue perfusion and oxygen delivery, also shown by
the significantly better intraoperative diuresis which
might have led to better outcomes. Indeed, it has been
shown that there is strong relationship between ScvO2
and anaemia causing an altered VO2/DO2 balance
[30].Fluid intake and outcome
In the ScvO2 group patients received more colloid boluses.
This is similar to a recent paper by Goepfert et al., in
which goal-directed therapy in patients undergoing
cardiac surgery, using stroke volume variation and opti-
mised global end diastolic volume index, resulted in
significantly more colloid administration both intraopera-
tively and in the ICU alike, and was accompanied by better
outcomes [31]. In our study the number of patients with
complications was lower in the ScvO2 group who had3 4 5
ion (hours)
Control
ScvO2
ean and standard deviation
Table 3 Postoperative complications within 48 h after the operation. Data are shown as number of patients with each complication.
KDIGO: Kidney Disease Improving Global Outcomes staging
ScvO2 (n = 38) Control (n = 41) p
Infection
Respiratory 0 1 0.33
Abdominal 2 2 0.94
Urinary tract 0 1 0.33
Wound 0 0 -
Mechanical ventilation > 24 h 1 5 0.11
Circulation
Cardiac decompensation 0 0 -
Arrhythmia 1 4 0.19
Vasopressor need 9 14 0.31
Acute myocardial infarction 0 0 -
Stroke 0 0 -
Abdominal
Constipation 2 3 0.71
Upper gastrointestinal bleeding 0 1 0.33
Re-operation 1 2 0.60
Urine output < 500 ml/24 h or haemodialysis 1 3 0.34
Postoperative surgical bleeding 1 1 0.96
Perioperative deaths 0 1 0.33
Number of patients with complications 10 19 0.07
PaO2/FiO2
>300 Hgmm 4 3 0.62
200–300 Hgmm 24 15 0.02*
100–200 Hgmm 10 22 0.01*
<100 Hgmm 0 1 0.52
Acute kidney injury
no injury 27 29 0.59
KDIGO 1 7 10 0.36
KDIGO 2 3 1 0.28
KDIGO 3 1 1 0.73
*: p<0.05
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difference was not significant.
Despite the increased fluid administration and transfu-
sion, gas exchange was not affected as indicated by the
PaO2/FiO2 ratio, which was actually higher in the ScvO2
group. We couldn’t identify any early adverse effects
from the use of colloid solution as indicated by the renal
function tests. Although there was significantly higher
28 day survival in the ScvO2 group, but the study wasn’t
powered to measure the effect on survival, hence the
sample size is too small to draw any conclusion regard-
ing postoperative mortality.
Regarding intraoperative fluid management, there is
large body of evidence that “restrictive” fluid strategy
during major surgery is superior to “liberal” protocols
[32, 33]. This is certainly true when only basic moni-
toring (blood pressure, heart rate, urine output) is
applied. However, whenever advanced haemodynamic
targets are used, treatment can be individualised, in
other words tailored to the patients’ actual need ratherthan simply just treating protocol based numbers
(MAP or CVP), which may be beneficial for some, but
may harm others [34]. There is mounting evidence
that dynamic physiological indices based approaches
are more beneficial than conventional treatments for
patients undergoing high risk surgery [31, 35]. These
are also in accordance with the findings of the recent
OPTIMISE trial [36], which although could not show
any significant reduction in the primary outcome
(complication rate at 30 days) in the cardiac output
guided group, there was a measurable treatment effect,
and at 180 days there was a non-significant reduction
in mortality.
CVP vs. ScvO2 as therapeutic targets
It has been shown that static preload parameters, in-
cluding CVP, have limited clinical value in guiding
heaemodynamic support and may also be inadequate
for predicting fluid responsiveness [10, 37]. In our
study there was no significant difference at any time
Mikor et al. BMC Anesthesiology  (2015) 15:82 Page 9 of 10point either between, or within groups for CVP, while
ScvO2 did change and reached a significant difference
between the groups over time. During anaesthesia oxy-
gen consumption is lower than while awake, and both
oxygen uptake and demand are more-or-less steady.
Therefore, it is reasonable to assume that changes in
ScvO2 mainly reflected changes in cardiac output and
oxygen supply. It has also been shown that there is
poor relationship between ventricular filling pressure
and ventricular volume, hence CVP is a very crude
measure of haemodynamic changes. This relationship
could further be disturbed by diastolic dysfunction and
altered ventricular compliance [38]. Despite all these
data, CVP measurement is still more widely used com-
pared to ScvO2 in the intraoperative setting [15].
There was a non-significant gradual decrease in ScvO2
in both groups towards the end of surgery, reaching the
targeted 75 % in the ScvO2 group. There was no signifi-
cant difference between the groups initially, but after 4 h
ScvO2 remained significantly higher in the control
group. Whilst there is general consensus that low venous
oxygen saturations are an important warning sign for
the inadequacy of oxygen delivery [39], high values are
more difficult to interpret. High values may mean re-
duced demand, but may also mean inadequate uptake
[40, 41]. Although we cannot prove it, we cannot ex-
clude that the high ScvO2 values in the control group
may have been the result of inadequate fluid loading
causing reduced oxygen uptake.
Limitations of the study
Although we did perform a power analysis to determine
the sample size, this was still a relatively small single
centre study. As a result the largest proportion of pa-
tients consisted of those who underwent radical cystec-
tomy, which may hinder the application of the results
for all types of major surgery. Furthermore, neither
cardiac output, nor pulse pressure or stroke volume var-
iations were monitored for more precise haemodynamic
evaluation. We commenced this study before we had the
results of one of our recent multicentre studies on pulse
pressure variation/cardiac index/MAP guided intraoper-
ative management [35]. On the other hand, continuous
monitoring of dynamic parameters such as SVV or PPV
are not the part of the routine haemodynamic assess-
ment and management during these operations. How-
ever, regarding these procedures, introduction of a
central venous line is part of the routine approach,
therefore the measurement of ScvO2 provided an
easily obtainable alternative for optimising intraopera-
tive haemodynamics. Finally, depth of anaesthesia
measurement with bispectral index monitoring was not
applied although it is well known that awareness can
have a significant effect on hemodynamic responses.However, as the anaesthetic protocols were the same in
both groups, and as the MAC values and opioid con-
sumption were also similar it is felt that this may not
impact on the results.
Conclusions
In the current study, using ScvO2 as a haemodynamic
end-point in addition to MAP, resulted in more intra-
operative fluid administration and transfusion during
major abdominal surgery. Based on our results, as the
insertion of a central venous line is part of the routine
management of these surgical procedures, instead of
advanced haemodynamic monitoring, ScvO2 assisted
intraoperative haemodynamic management may be a
useful alternative and may also lead to improved out-
comes. This study also supports our previous assump-
tion that if ScvO2 is used during general anaesthesia,
higher levels should be considered as a target value
than in the critical care setting.
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